Daiichi Sankyo (Manufacturing / Daiichi Sankyo Propharma)
Tokyo, Japan
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Daiichi Sankyo (Manufacturing / Daiichi Sankyo Propharma)
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Tokyo, Japan
- Modalities
- ADC (Antibody-Drug Conjugate), Small Molecule API, Biologics (mAb), Sterile Injectables / Fill-Finish
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Daiichi Sankyo (Manufacturing / Daiichi Sankyo Propharma)
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesADC (Antibody-Drug Conjugate), Small Molecule API, Biologics (mAb), Sterile Injectables / Fill-Finish
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (4 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Broad modality coverage (4 modalities)
Frequently Asked Questions About Daiichi Sankyo (Manufacturing / Daiichi Sankyo Propharma)
What is Daiichi Sankyo (Manufacturing / Daiichi Sankyo Propharma)'s CDMO Signal Score?
Daiichi Sankyo (Manufacturing / Daiichi Sankyo Propharma) has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Daiichi Sankyo (Manufacturing / Daiichi Sankyo Propharma) for a manufacturing program?
Use the free AI matchmaker to compare Daiichi Sankyo (Manufacturing / Daiichi Sankyo Propharma) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Novasep
Lyon, France
Small Molecule API, HPAPI / High-Potency API, ADC (Antibody-Drug Conjugate), Lentiviral Vector, Biologics (Recombinant Proteins, mAbs), Oligonucleotide, Peptide, Chromatography / Purification Services
WuXi XDC
Shanghai, China
ADC (Antibody-Drug Conjugate), Bioconjugates (XDC), mAb intermediates, Payload-linker synthesis, Drug substance (DS), Drug product (DP), Bispecific ADCs, RDC (Radioimmunoconjugates), AOC / DAC / APC
Olon Group
Rodano (Milan), Italy
Small Molecule API, HPAPI / Cytotoxics, Microbial Fermentation, Mammalian Cell Culture, Recombinant Proteins / Enzymes, Biologics (mAbs), ADC (end-to-end bioconjugation), Oligonucleotide / Peptide, Chemical Synthesis, Semi-Synthesis
Fermion (Orion Group)
Espoo, Finland
Small Molecule API, HPAPI, Semi-solid drug product (creams, gels, ointments), Hormonal products
Sun Pharmaceutical Industries Ltd.
Mumbai, India
Small Molecule API, Oral Solid Dose, Sterile Injectables, Specialty Generics, Novel Chemical Entities (NCE) via CRAMS, Biologics (via CMO partnerships), Specialty/Innovative Medicines